

Revision Date 28-Dec-2023 Revision Number 8

SECTION 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Description: ImmunoCAP Phadiatop Infant

Cat No.: 14-4510-41

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use In vitro diagnostic Uses advised against All other uses

1.3. Details of the supplier of the safety data sheet

Company Phadia AB

Rapsgatan 7P P.O. Box 6460 751 37 UPPSALA

Sweden

+46 18 16 50 00

E-mail address safetydatasheet.idd@thermofisher.com

1.4. Emergency telephone number

CHEMTREC Ireland (Dublin) +(353)-19014670 CHEMTREC Belgium (Brussels) +(32)-28083237

Malta 112 Emergency phone number

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

CLP Classification - Regulation (EC) No 1272/2008

Physical hazards

Based on available data, the classification criteria are not met

Health hazards

Based on available data, the classification criteria are not met

Environmental hazards

Based on available data, the classification criteria are not met

For the full text of the H-statements mentioned in this Section, see Section 16.

2.2. Label elements

Revision Date 28-Dec-2023

EUH208 - Contains (reaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H -isothiazol-3- one [EC no. 220-239-6] (3:1); (CMIT/MIT (3:1))). May produce an allergic reaction.

2.3. Other hazards

May produce an allergic reaction This product does not contain any known or suspected endocrine disruptors. This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor very bioaccumulating (vPvB).

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substances

3.2. Mixtures

| Component | CAS No | EC No | Weight % | CLP Classification - Regulation (EC) No 1272/2008 |
|---|------------|-------|----------|--|
| 5-Chloro-2-methyl-3(2H)-isothiazol one, mixture with 2-methyl-3(2H)-isothiazolone | 55965-84-9 | | <0.0015 | Acute Tox. 3 (H301) Acute Tox. 2 (H310) Acute Tox. 2 (H330) Skin Corr. 1C (H314) Eye Dam. 1 (H318) Skin Sens. 1A (H317) Aquatic Acute 1 (H400) Aquatic Chronic 1 (H410) EUH071 |

| Component | Specific concentration limits | M-Factor | Component notes |
|---|---------------------------------|---------------|-----------------|
| | (SCL's) | | |
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | Eye Irrit. 2 (H319) :: | 100 (acute) | = |
| mixture with 2-methyl-3(2H)-isothiazolone | 0.06%<=C<0.6% | 100 (chronic) | |
| | Skin Corr. 1C (H314) :: C>=0.6% | | |
| | Skin Irrit. 2 (H315) :: | | |
| | 0.06%<=C<0.6% | | |
| | Skin Sens. 1A (H317) :: | | |
| | C>=0.0015% | | |
| | Eye Dam. 1 (H318) :: C>=0.6% | | |

For the full text of the H-statements mentioned in this Section, see Section 16.

SECTION 4: FIRST AID MEASURES

4.1. Description of first aid measures

Eye Contact Rinse thoroughly with plenty of water, also under the eyelids.

Skin Contact Wash off immediately with soap and plenty of water.

Ingestion Clean mouth with water and drink afterwards plenty of water.

ImmunoCAP Phadiatop Infant Revision Date 28-Dec-2023

Inhalation Not applicable.

Self-Protection of the First Aider Not Applicable.

4.2. Most important symptoms and effects, both acute and delayed

No information available.

4.3. Indication of any immediate medical attention and special treatment needed

Notes to Physician Treat symptomatically.

SECTION 5: FIREFIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Extinguishing media which must not be used for safety reasons

None known.

5.2. Special hazards arising from the substance or mixture

None known.

Hazardous Combustion Products

None known.

5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Wear protective gloves/clothing and eye/face protection.

6.2. Environmental precautions

Dispose of in accordance with local regulations.

6.3. Methods and material for containment and cleaning up

Wipe up with adsorbent material (e.g. cloth, fleece). Dispose of waste product or used containers according to local regulations.

6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

ImmunoCAP Phadiatop Infant

Revision Date 28-Dec-2023

Wash thoroughly after handling. Do not eat, drink or smoke when using this product.

7.2. Conditions for safe storage, including any incompatibilities

Keep at temperatures between 2 and 8°C.

7.3. Specific end use(s)

Observe instructions for use.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure limits

List source(s): **CH** - The Government of Switzerland has set a directive on limit values for working materials (Grenzwerte am Arbeitsplatz) which is based on the Swiss Federal Regulation "Verordnung über die Verhütung von Unfällen und Berufskrankheiten". This directive is administered, periodically revised and enforced by SUVA (Swiss National Accident Insurance Fund).

| Component | Austria | Denmark | Switzerland | Poland | Norway |
|-----------------------|---------------------------------|---------|--------------------------------|--------|--------|
| 5-Chloro-2-methyl-3(| MAK-TMW: 0.05 mg/m ³ | | STEL: 0.4 mg/m ³ 15 | | |
| 2H)-isothiazolone, | 8 Stunden | | Minuten | | |
| mixture with | | | TWA: 0.2 mg/m ³ 8 | | |
| 2-methyl-3(2H)-isothi | | | Stunden | | |
| azolone | | | | | |

Biological limit values

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

Monitoring methods

BS EN 14042:2003 Title Identifier: Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.

Derived Minimum Effect Level (DMEL) / Derived No Effect Level (DNEL)

See table for values

| Component | Acute effects local | Acute effects | Chronic effects local | Chronic effects |
|---------------------------------|-----------------------------|-----------------------|-----------------------|-----------------------|
| | (Inhalation) | systemic (Inhalation) | (Inhalation) | systemic (Inhalation) |
| 5-Chloro-2-methyl-3(2H)-isothia | $DNEL = 0.04 \text{mg/m}^3$ | | $DNEL = 0.02mg/m^3$ | |
| zolone, mixture with | | | | |
| 2-methyl-3(2H)-isothiazolone | | | | |
| 55965-84-9 (<0.0015) | | | | |

Predicted No Effect Concentration (PNEC)

See values below.

| Component | Fresh water | Fresh water | Water Intermittent | Microorganisms in | Soil (Agriculture) |
|-----------|-------------|-------------|--------------------|-------------------|--------------------|
| | | | | | |

ImmunoCAP Phadiatop Infant

Revision Date 28-Dec-2023

| | | sediment | | sewage treatment | |
|--|-----------------------|---------------------------|----------------------|------------------|------------------|
| 5-Chloro-2-methyl-3(2H)-is | $PNEC = 3.39 \mu g/L$ | PNEC = | PNEC = $3.39\mu g/L$ | PNEC = 0.23mg/L | PNEC = 0.01mg/kg |
| othiazolone, mixture with 2-methyl-3(2H)-isothiazolo | | 0.027mg/kg sediment dw | | - | soil dw |
| ne 55965-84-9 (<0.0015) | | | | | |

| Component | Marine water | Marine water sediment | Marine water Intermittent | Food chain | Air |
|---|--------------|-------------------------------------|------------------------------|------------|-----|
| 5-Chloro-2-methyl-3(2H)-is othiazolone, mixture with 2-methyl-3(2H)-isothiazolo | . • | PNEC = 0.027mg/kg sediment dw | PNEC = 3.39μg/L | | |
| ne 55965-84-9 (<0.0015) | | | | | |

8.2. Exposure controls

Engineering Measures

None under normal use conditions.

Personal protective equipment

Eye Protection No special protective equipment required.

Hand Protection No special protective equipment required.

| Glove material | Breakthrough time | Glove thickness | EU standard | Glove comments |
|----------------|-------------------|-----------------|-------------|----------------|
| | | - | | |

Skin and body protection No special protective equipment required.

Respiratory ProtectionNo protective equipment is needed under normal use conditions.

Large scale/emergency use No protective equipment is needed under normal use conditions

Small scale/Laboratory use No personal respiratory protective equipment normally required.

Hygiene Measures Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure controls Dispose of contents/containers in accordance with local regulations.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical State Liquid

Appearance Transparent
Odor None
Odor Threshold None

Melting Point/RangeNo data availableSoftening PointNo data availableBoiling Point/RangeNo data availableFlammability (liquid)No data availableFlammability (solid,gas)No information availableExplosion LimitsNo data available

ImmunoCAP Phadiatop Infant Revision Date 28-Dec-2023

Method - No information available

(Air = 1.0)

No data available

Autoignition Temperature No data available
Decomposition Temperature No data available

oH 7.2-7.6

Viscosity

Water Solubility

Soluble in water

No information available

No information available

Partition Coefficient (n-octanol/water)
Component log Pow

5-Chloro-2-methyl-3(2H)-isothiazolone, <0.401

mixture with

Flash Point

2-methyl-3(2H)-isothiazolone

Vapor PressureNo data availableDensity / Specific Gravity1.1 g/cm3Bulk DensityNo data availableVapor DensityNo data available

Particle characteristics Not applicable (liquid)

9.2. Other information

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity

None known.

10.2. Chemical stability

Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous Polymerization Hazardous polymerization does not occur.

Hazardous Reactions None under normal processing.

10.4. Conditions to avoid

None known.

10.5. Incompatible materials

None known.

10.6. Hazardous decomposition products

None known.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Product Information Product does not present an acute toxicity hazard based on known or supplied information.

(a) acute toxicity;

Oral No data available.

Dermal No data available.

Inhalation No data available.

| Component | LD50 Oral | LD50 Dermal | LC50 Inhalation |
|---|-----------------------|-----------------------------|----------------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | LD50 = 53 mg/kg (Rat) | LD50 = 87.12 mg/kg (Rabbit) | 4h 0.33 mg/l (Rat) |
| mixture with 2-methyl-3(2H)-isothiazolone | | | j , , , |

ImmunoCAP Phadiatop Infant

(b) skin corrosion/irritation; No data available.

(c) serious eye damage/irritation; No data available.

(d) respiratory or skin sensitization;

Respiratory SkinNo data available.
No data available.

(e) germ cell mutagenicity; No data available.

| Component | Test method | Test species | Study result |
|---|-------------|--------------|--------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | in vivo | | negative |
| mixture with 2-methyl-3(2H)-isothiazolone | in vitro | | _ |

(f) carcinogenicity; There are no known carcinogenic chemicals in this product.

| Component | Test method | Test species / Duration | Study result |
|---|-------------|-------------------------|--------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | | | negative |
| mixture with 2-methyl-3(2H)-isothiazolone | | | _ |

(g) reproductive toxicity; No data available.

| Component | Test method | Test species / Duration | Study result |
|---|-------------|-------------------------|---------------------------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | | | negative |
| mixture with 2-methyl-3(2H)-isothiazolone | | | Animal testing did not show any |
| | | | effects on fetal development |

(h) STOT-single exposure; No data available.

(i) STOT-repeated exposure; No data available.

(j) aspiration hazard; No data available.

Symptoms / effects,both acute and delayed No information available.

11.2. Information on other hazards

Endocrine Disrupting Properties This product does not contain any known or suspected endocrine disruptors.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity Ecotoxicity effects

| Component | Freshwater Fish | Water Flea | Freshwater Algae | Microtox |
|---|-----------------------|----------------------|------------------------|--------------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | Acute toxicity: | Acute toxicity: | Acute toxicity: | Chronic toxicity: |
| mixture with 2-methyl-3(2H)-isothiazolone | LC50 96 h 0.19mg/l | EC50 48 h 0.126 mg/l | ERC50 72 h 0.027 mg/l | NOEC 3h 0.91 mg/l |
| | (Oncorhynchus mykiss) | (Daphnia magna) | (Selenastrum | (Activated sludge) |
| | EPA OPP 72-1 | OECD Test 202 | capricornutum) | OECD 209 |
| | | | | |
| | Chronic toxicity: | Chronic toxicity: | Chronic toxicity: | |
| | NOEC 35 days 0.02 | NOEC 21 days | NOEC 96h 0.004 mg/l, | |
| | mg/l (Pimephales | 0.10 mg/l | (Skeletonema costatum) | |
| | promelas) OECD 210 | (Daphnia magna) | OECD 201 | |

Revision Date 28-Dec-2023

ImmunoCAP Phadiatop Infant

Revision Date 28-Dec-2023

12.2. Persistence and degradability Product is biodegradable.

| Component | Degradability |
|---|--------------------------------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | Biodegradable <50 % 10 days |
| mixture with 2-methyl-3(2H)-isothiazolone | Atmospheric half-life: 0.38-1.3 Days |

12.3. Bioaccumulative potential Bioaccumulation is unlikely.

| Component | log Pow | Bioconcentration factor (BCF) |
|---|---------|-------------------------------|
| 5-Chloro-2-methyl-3(2H)-isothiazolone, | <0.401 | <54 |
| mixture with 2-methyl-3(2H)-isothiazolone | | |

12.4. Mobility in soil No information available.

12.5. Results of PBT and vPvB

assessment

This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor

very bioaccumulating (vPvB).

12.6. Endocrine disrupting

properties

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors

12.7. Other adverse effects

Persistent Organic Pollutant Ozone Depletion Potential No known effect. No known effect.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from Residues/Unused

Products

Dispose of in accordance with local regulations.

Contaminated Packaging Dispose of in accordance with local regulations.

European Waste Catalogue (EWC)

Other Information

18 01 07 Chemicals other than those mentioned in 18 01 06.

No information available.

SECTION 14: TRANSPORT INFORMATION

IMDG/IMO Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

ADR Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

IATA Not regulated

ImmunoCAP Phadiatop Infant Revision Date 28-Dec-2023

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

14.5. Environmental hazards No hazards identified.

14.6. Special precautions for user No special precautions required.

14.7. Maritime transport in bulk

according to IMO instruments

Not applicable, packaged goods.

SECTION 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories X = listed

| Component | EINECS | ELINCS | NLP | TSCA | DSL | NDSL | PICCS | ENCS | IECSC | AICS | KECL |
|--------------------------------|--------|--------|-----|------|-----|------|-------|------|-------|------|---------|
| 5-Chloro-2-methyl-3(2H)-isothi | - | - | | - | Х | - | Χ | Χ | Χ | - | KE-0573 |
| azolone, mixture with | | | | | | | | | | | 8 |
| 2-methyl-3(2H)-isothiazolone | | | | | | | | | | | 1 |

| Component | REACH (1907/2006) - Annex XIV - Substances Subject to Authorization | REACH (1907/2006) - Annex XVII - Restrictions on Certain Dangerous Substances | |
|---|---|---|--|
| 5-Chloro-2-methyl-3(2H)-isothiaz olone, mixture with 2-methyl-3(2H)-isothiazolone | | Use restricted. See item 75. (see link for restriction details) | |

| Component | Seveso III Directive (2012/18/EC) - Qualifying Quantities for Major Accident Notification | Seveso III Directive (2012/18/EC) - Qualifying Quantities for Safety Report Requirements |
|----------------------------------|--|--|
| 5-Chloro-2-methyl-3(2H)-isothiaz | H1: 5-100 ton, E1: 20-200 ton | H1: 5-100 ton, E1: 20-200 ton |
| olone, mixture with | | |
| 2-methyl-3(2H)-isothiazolone | | |

Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

National Regulations

| Component | Germany - Water Classification (AwSV) | Germany - TA-Luft Class |
|----------------------------------|---------------------------------------|-------------------------|
| 5-Chloro-2-methyl-3(2H)-isothiaz | WGK3 | |
| olone, mixture with | | |
| 2-methyl-3(2H)-isothiazolone | | |

UK - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment.

15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) is not required.

SECTION 16: OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3

H301 - Toxic if swallowed

H310 - Fatal in contact with skin

H314 - Causes severe skin burns and eye damage

ImmunoCAP Phadiatop Infant

Revision Date 28-Dec-2023

H317 - May cause an allergic skin reaction

H318 - Causes serious eve damage

H330 - Fatal if inhaled

H400 - Very toxic to aquatic life

H410 - Very toxic to aquatic life with long lasting effects

EUH071 - Corrosive to the respiratory tract EUH208 - May produce an allergic reaction

Legend

CAS - Chemical Abstracts Service

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory DSL/NDSL - Canadian Domestic Substances List/Non-Domestic

ENCS - Japanese Existing and New Chemical Substances

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances **IECSC** - Chinese Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

WEL - Workplace Exposure Limit

ACGIH - American Conference of Governmental Industrial Hygienists

DNEL - Derived No Effect Level

RPE - Respiratory Protective Equipment LC50 - Lethal Concentration 50% NOEC - No Observed Effect Concentration PBT - Persistent, Bioaccumulative, Toxic

TWA - Time Weighted Average **IARC** - International Agency for Research on Cancer

AICS - Australian Inventory of Chemical Substances

Predicted No Effect Concentration (PNEC)

LD50 - Lethal Dose 50%

Substances List

EC50 - Effective Concentration 50% POW - Partition coefficient Octanol:Water vPvB - very Persistent, very Bioaccumulative

ADR - European Agreement Concerning the International Carriage of Dangerous Goods by Road

IMO/IMDG - International Maritime Organization/International Maritime Dangerous Goods Code

OECD - Organisation for Economic Co-operation and Development

BCF - Bioconcentration factor

ICAO/IATA - International Civil Aviation Organization/International Air Transport Association

MARPOL - International Convention for the Prevention of Pollution from

ATE - Acute Toxicity Estimate VOC (volatile organic compound)

Key literature references and sources for data

https://echa.europa.eu/information-on-chemicals

Suppliers safety data sheet, Chemadvisor - LOLI, Merck index, RTECS

On basis of test data Physical hazards **Health Hazards** Calculation method **Environmental hazards** Calculation method

Training Advice

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and hygiene.

28-Dec-2023 **Revision Date**

Revision Summary SDS sections updated, 7.

This safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006 COMMISSION REGULATION (EU) 2020/878 amending Annex II to Regulation (EC) No 1907/2006

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

End of Safety Data Sheet